Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish

  1. Robyn S Allen
  2. Benjamin Tajer
  3. Eileen M Shore
  4. Mary C Mullins  Is a corresponding author
  1. Department of Cell and Developmental Biology University of Pennsylvania Perelman School of Medicine, United States
  2. Departments of Orthopaedic Surgery and Genetics University of Pennsylvania Perelman School of Medicine, United States
7 figures, 1 table and 1 additional file

Figures

Figure 1 with 2 supplements
ACVR1-R206H and -G328R over-activate BMP signaling in the absence of an intact ligand-binding domain.

(a) Embryos expressing ACVR1 HA-tagged constructs were immunostained for HA at the shield stage (early gastrula); ACVR1 domain schematics of the constructs are above each set of corresponding images. Nuclei (yellow), βcatenin (cyan), ACVR1-HA (magenta). Scale bars = 40 μm. ΔAcvr1 constructs lack residues 35–100, which contain the cysteine-rich ligand binding motifs. Uninjected (N = 6) and embryos injected with: Acvr1 (N = 6), ΔAcvr1 (N = 5), Acvr1-R206H (N = 9), ΔAcvr1-R206H (N = 4), Acvr1-G328R (N = 5), and ΔAcvr1-G328R (N = 5). (b) BMP signaling dose-dependent 12–30 hpf zebrafish embryo phenotypes: severe dorsalization (C5-C4, dark blue), mild dorsalization (C3-C1, light blue), wild-type development (WT, violet), mild ventralization (V1-V3, light orange), and severe ventralization (V4-V5, dark orange). (c) Bubble plot circle sizes correspond to the percent of total embryos within a condition that are in a particular phenotypic category. Examples are shown for: 100%, 90%, 80%, 70%, 60%, 50%, 40%, 30%, 20% and 10%. (d) Representative phenotypes of wild-type embryos (evaluated at 12 and 30 hpf) and embryos injected with acvr1l MO (evaluated at 12 hpf; none survive to 30 hpf). (e–g) DV phenotypes of 12–30 hpf embryos injected with Acvr1 or ΔAcvr1 mRNA alone or together with acvr1l MO. Data are from four pooled experiments. (e) Acvr1 or ΔAcvr1 injected embryos. Columns: 1, N = 240; 2, N = 121; 3, N = 140; 4, N = 153; 5, N = 96; 6, N = 118. (e’) Representative 12 or 30 hpf phenotypes. (f) Acvr1-R206H or ΔAcvr1-R206H injected embryos. Columns: 1, N = 240; 2, N = 70; 3, N = 84; 4, N = 153; 5, N = 73; 6, N = 91. (f’) Representative 30 hpf phenotypes. (g) Acvr1-G328R or ΔAcvr1-G328R injected embryos. Columns: 1, N = 240; 2, N = 88; 3, N = 79; 4, N = 153; 5, N = 78; 6, N = 71. (g’) Representative 30 hpf phenotypes.

Figure 1—figure supplement 1
ACVR1-R206H and -G328R over-activate BMP signaling causing ventralization in the absence of an intact ligand-binding domain.

Representative 12–14 and 30 hpf phenotypes of injected embryos.

Figure 1—figure supplement 2
Ventralizing amounts of Acvr1-R206H and Acvr1-G328R are comparable to rescuing amounts of Acvr1.

12–30 hpf embryos injected with Acvr1 or ΔAcvr1 mRNA alone or together with acvr1l MO. Data are from two pooled experiments. Embryos in a and b are siblings injected on the same plate with each MO or mRNA in the same calibrated needle (a) DV phenotypes. Columns: 1, N = 70; 2, N = 62; 3, N = 18; 4, N = 28; 5, N = 28; 6, N = 31; 7, N = 53; 8, N = 80; 9, N = 21; 10, N = 20; 11, N = 34; 12, N = 45; 13, N = 52; 14, N = 49. (b) HA-tag fluorescence per μm2 of β-catenin expression of embryos injected in a. All imaged embryos were WT (with no Acvr1 KD). Uninjected embryos N = 6, Acvr1 injected N = 5, Acvr1-R206H injected N = 7, Acvr1-G328R N = 7, ΔAcvr1 injected N = 6, ΔAcvr1-R206H injected N = 7, ΔAcvr1-G328R N = 6. Horizontal bars indicate statistical significance based on a two-tailed t-test assuming unequal variance (* indicates p<0.05, ns indicates no significance).

ACVR1-R206H and -G328R over-activate pSmad1/5 signaling with or without the presence of a ligand-binding domain.

(a,a’–g,g’) Animal pole view of relative pSmad1/5 intensities (using arbitrary units (AU)) within each nucleus of the embryo in representative WT early-gastrula embryos (shield-65% epiboly stage) with endogenous Acvr1l present (a–g) or knocked down (a’–g’). Injected mRNAs are noted above for b-g and b’-g’. (a–c, a’–c’) Embryos are oriented with ventral (V) side to the left and the dorsal (D) side to the right. (d–g, d’–g’) Dorsal side of the embryo could not be identified due to loss of the shield structure with severe ventralization. Scale bars = 100 μm. (a, a’) Wild-type and Acvr1l-KD embryos, respectively (N = 18 and 15). (b, b’) Acvr1 injected embryos (N = 10 and 9). (c, c’) ΔAcvr1 injected embryos (N = 9 and 7). (d, d’) Acvr1-R206H injected embryos (N = 14 and 17). (e, e’) ΔAcvr1-R206H injected embryos (N = 8 and 11). (f, f’) Acvr1-G328R injected embryos (N = 12 and 9). (g, g’) ΔAcvr1-G328R injected embryos (N = 12 and 12). (h) Mean nuclear pSmad1/5 fluorescence of injected embryos. Each dot represents the mean nuclear fluorescence for an individual embryo. Mean and standard deviation of each condition are shown by bars. * indicates p<0.05, ** indicates p<0.001, ns indicates no significance.

Figure 3 with 2 supplements
ACVR1-R206H and -G328R but not ΔAcvr1-R206H are responsive to Bmp7 ligand.

(a) Representative dorsal-ventral (DV) phenotypes of bmp7-/- embryos not injected (12 hpf), injected with bmp7 mRNA (12 and 30 hpf), or bmp7 mRNA and acvr1l KD (12–14 hpf). (b–d) 12–30 hpf DV phenotypes of bmp7-/- embryos with acvr1l KD that were injected with human ACVR1 mRNA alone or combined with bmp7 mRNA. (b) WT ACVR1 injected embryos. Three pooled experiments. Columns: 1, N = 240; 2, N = 150; 3, N = 143; 4, N = 101; 5, N = 120. (b’) Representative 12 and 30 hpf phenotypes. (c) ACVR1-R206H injected embryos. Two pooled experiments. Columns: 1, N = 177; 2, N = 78; 3 N = 132; 4, N = 100; 5, N = 86. (c’) Representative 12 and 30 hpf phenotypes. (d) ACVR1-G328R injected embryos. Two pooled experiments. Columns: 1, N = 52; 2, N = 46; 3, N = 55; 4, N = 56; 5, N = 82. (d’) Representative 12 and 30 hpf phenotypes. (e–f) 12–30 hpf DV phenotypes of bmp7-/- embryos with acvr1l KD that were injected with a mouse Acvr1 or ΔAcvr1 mRNA alone or in combination with bmp7 mRNA. Four pooled experiments. (e) WT Acvr1 or ΔAcvr1 mRNA Columns: 1, N = 540; 2, N = 172; 3, N = 143; 4, N = 152; 5, N = 231; 6, N = 163; 7, N = 104; 8, N = 97; (f) Acvr1-R206H or ΔAcvr1-R206H mRNA Columns: 1, N = 540; 2, N = 172; 3, N = 143; 4, N = 152; 5, N = 176; 6, N = 217; 7, N = 119; 8, N = 145.

Figure 3—figure supplement 1
ACVR1-R206H and ACVR1-G328R are responsive to BMP7 ligand.

Representative 12–14 and 30 hpf phenotypes of injected embryos.

Figure 3—figure supplement 2
Unlike Acvr1-R206H, neither ΔAcvr1-R206H nor ΔAcvr1 responds to Bmp7 ligand.
ACVR1-R206H requires a ligand-binding domain to respond to BMP7 and Activin A ligand through pSmad1/5.

(a, b) Representative 6 hpf (shield stage) WT (a) and bmp7-/- (b) embryos uninjected or injected with Activin A mRNA. WT and bmp7-/- develop normal dorsal organizers (arrows). Activin A injection causes embryos to have expanded (filled arrowheads) or duplicated (empty arrowheads) dorsal organizers. (c–m) Animal pole view of pSmad1/5 intensities (using arbitrary units (AU)) within each nucleus of the embryo in representative bmp7-/- early gastrula (shield stage) embryos with endogenous Acvr1l present (c–e) or knocked down (f–m). Injected receptor mRNA is noted to the left and ligand mRNA is noted above. Embryos are oriented with the dorsal shield to the right. Scale bars = 100 μm. (c–e) bmp7-/- uninjected embryos (N = 8), or injected with bmp7 (N = 10), or Activin A (N = 8) mRNA. (f and g) bmp7-/-, acvr1l KD embryos injected with bmp7 (N = 6) or Activin A (N = 8) mRNA. (h–j) Acvr1-R206H injected bmp7-/-, acvr1l KD embryos with no injected ligand (N = 8), bmp7 (N = 8), or Activin A (N = 9) mRNA. (k–m) ΔAcvr1-R206H injected bmp7-/-, acvr1l KD embryos (N = 11), with injected bmp7 (N = 11), or Activin A (N = 11) mRNA. (n) Mean nuclear pSmad1/5 fluorescence of injected embryos. Each dot represents the mean fluorescence of an individual embryo. Mean and standard deviation of each condition is shown. * indicates p<0.05, ns indicates no significance. (o–s) Lateral views showing relative pSmad2 intensities (using arbitrary units (AU)) within each nucleus of the embryo in representative bmp7-/- early gastrula embryos (shield stage) with endogenous acvr1l present (i and j) or knocked down (k–m). Injected mRNA is noted above each image. Embryos are oriented with the presumptive dorsal side facing forward. Scale bars = 100 μm. (o) bmp7-/- embryo (N = 5) (p) Activin A injected embryo (N = 8) (q) Activin A injected embryo with Acvr1l knockdown (N = 5) (r) mAcvr1-R206H injected embryo with Acvr1l knockdown (N = 5) (s) mAcvr1-R206H and Activin A injected embryo with Acvr1l knockdown (N = 5) (t) Mean nuclear pSmad2 fluorescence of injected embryos. Each dot represents the mean fluorescence of an individual embryo. Mean and standard deviation of each condition is shown by bars. * indicates p<0.05, ns indicates no significance.

Figure 5 with 2 supplements
ACVR1-R206H signals in the absence of BMPR1.

(a) Experimental workflow. bmpr1aa+/-; ab-/- fish were crossed with each other to generate bmpr1a+/- (bmpr1aa+/+; ab-/-), bmpr1a+/- (bmpr1aa+/-; ab-/-), and bmpr1a-/- (bmpr1aa-/-;ab-/-) embryos. One-cell stage eggs were injected with bmpr1ba, bmpr1bb morpholinos, and separately injected with an acvr1l morpholino to additionally knockdown these endogenous BMP receptors, and then were injected with ACVR1-R206H mRNA. Early gastrula (shield-65% epiboly) stage embryos were collected and fixed for immunostaining. At 12 to 30 hpf the remaining embryos were scored for DV patterning phenotypes. Following blindly immunostaining and imaging, or phenotyping, embryos were individually genotyped. (b) Representative immunostained embryo for ACVR1-Flag (magenta), β-Catenin (marking the cell membrane cyan), and nuclei (yellow) (N=5). (c-e) Representative 24 hpf phenotypes of (b) bmpr1aa+/+; ab-/-, (c) bmpr1aa+/-; ab-/-, and (d) bmpr1aa-/-; ab-/- embryos. (f) Injected embryo phenotypes at 12 to 30 hpf. Three pooled experiments. Columns: 1, N=104; 2, N=41; 3, N=69; 4, N=69; 5, N=78; 6, N=70; 7, N=36; 8, N=19; 9, N=25; 10, N=29; 11, N=23; 12, N=22. (g-j) Animal pole view of relative pSmad1/5 intensities (AU) within each nucleus in representative early-gastrula embryos. (d and f) Embryos are oriented with the ventral (V) side to the left and the dorsal (D) side to the right. (e and g) Dorsal side of the embryo could not be identified due to loss of the shield structure with ventralization. (g) bmpr1a+/- embryo (N=5). (h) bmpr1a+/- embryo injected with ACVR1-R206H mRNA (N=5). (i) bmpr1a-/- embryo with acvr1l and bmpr1b KD (Type I KD embryo) (N=4). (j) Type I KD embryo injected with ACVR1-R206H mRNA (N=5). (k) Mean nuclear pSmad1/5 fluorescence of injected embryos. Each dot represents the mean fluorescence of an individual embryo. Mean and standard deviation of each condition (e-h) is shown. * indicates P<0.05, ns indicates no significance.

Figure 5—figure supplement 1
ACVR1-R206H signals in the absence of all other type I BMP receptors.

Representative 12 and 30 hpf phenotypes of injected embryos. Dead C5 embryos were removed from 30 hpf live embryos prior to photographing. Orange asterisks indicate C5 bmpr1a-/- embryo with bmpr1b KD; indicating that loss of all Bmpr1 function eliminates BMP signaling.

Figure 5—figure supplement 2
ACVR1-G328R signals in the absence of all other type I BMP receptors.

Top bubble plots are from two pooled experiments. Columns: 1, N = 24; 2, N = 76; 3, N = 101; 4, N = 66; 5, N = 72; 6, N = 59; 7, N = 36; 8, N = 28; 9, N = 32; 10, N = 20; 11, N = 30; 12, N = 13. Lower panels are injected embryo phenotypes at 14 to 30 hpf. 14–16 hpf C5 embryos are in the process of lysing. Dead C5 embryos were removed from 30 hpf live embryos prior to photographing.

Figure 6 with 1 supplement
ΔACVR1-R206H signals in the absence of Bmpr1.

(a–b) Injected bmpr1a+/- or -/- 12 to 30 hpf embryo phenotypes with bmpr1b KD, acvr1 KD with or without Acvr1-R206H or ΔAcvr1-R206H mRNA. Two pooled experiments. (a) Acvr1-R206H injected embryos. Columns: 1, N = 150; 2, N = 80; 3, N = 98; 4, N = 89; 5, N = 76; 6, N = 36; 7, N = 31; 8, N = 30. (b) ΔAcvr1-R206H injected embryos. Columns: 1, N = 150; 2, N = 80; 3, N = 92; 4, N = 127; 5, N = 76; 6, N = 36; 7, N = 26; 8, N = 37. (c–i) Representative dorsal view of pax2.1 (white arrowheads: anteriorly in the midbrain-hindbrain boundary and posteriorly in the pronephric mesoderm), krox20 (black arrowheads; rhombomeres 3 and 5), and myod (black arrow; paraxial mesoderm) expression in 5–9 somite stage bmpr1a+/-or -/- embryos with bmpr1b KD, acvr1 KD with or without Acvr1-R206H or ΔAcvr1-R206H. Two independent experiments. Embryos are oriented with the anterior (A) side left and the posterior (P) side right. Number of embryos that showed expression patterns similar to the representative embryos out of the total number of embryos analyzed is shown. (c) bmpr1a+/- embryo (d) bmpr1a-/- embryo (e) bmpr1a-/-embryo with acvr1l and bmpr1b KD (Type I KD embryo) (f) Type I KD embryo injected with Acvr1-R206H mRNA. (g) Type I KD embryo injected with ΔAcvr1-R206H mRNA.

Figure 6—figure supplement 1
ΔACVR1-R206H signals in the absence of all other type I BMP receptors.

Representative 12 and 30 hpf phenotypes of injected embryos. Dead C5 embryos were removed from 30hpf live embryos prior to photographing.

Figure 7 with 1 supplement
ACVR1-R206H responds to ligand in the absence of all other type I BMP receptors.

(a) 12–30 hpf phenotypes of bmpr1a+/-or -/- embryos with bmpr1b KD and acvr1l KD with or without ACVR1-R206H, with or without chordin (chd) mRNA or bmp7 mRNA. Four pooled experiments plus two experiments with controls only. Columns: 1, N = 172; 2, N = 160; 3, N = 106; 4, N = 135; 5, N = 104; 6, N = 121; 7, N = 169; 8, N = 117; 9, N = 32; 10, N = 91; 11, N = 17; 12, N = 57; 13, N = 29; 14, N = 28; 15, N = 49; 16, N = 49. (b–g) Representative dorsal view of pax2.1, krox20, and myod expression in 5–9 somite stage bmpr1a+/-or -/- embryos with bmpr1b KD, acvr1 KD, with or without ACVR1-R206H, and with or without chordin or bmp7 mRNA. Three experiments. Embryos are oriented with the anterior (A) side left and the posterior (P) side right. Number of embryos that showed expression patterns similar to the representative embryos out of the total number of embryos analyzed is shown. (b) bmpr1a +/- embryo (c) bmpr1a-/-embryo (d) bmpr1a-/-embryo with acvr1l and bmpr1b KD (Type I KD embryo) (e) Type I KD embryo injected with ACVR1-R206H and chd mRNA (f) Type I KD embryo injected with ACVR1-R206H mRNA (g) Type I KD embryo injected with ACVR1-R206H and bmp7 mRNA.

Figure 7—figure supplement 1
ACVR1-R206H responds to ligand in the absence of all other type I BMP receptors Representative 12 and 30 hpf phenotypes of injected embryos.

Dead C5 embryos were removed from 30hpf live embryos prior to photographing. C4 (bmpr1aa-/-;ab-/-) and V5 (bmpr1a+/+;ab-/-) embryos indicated in bmpr1aa+/-;bmpr1ab-/-cross progeny injected with bmp7; showing that bmp7 overexpression does not rescue the bmpr1aa-/-;ab-/-C4 phenotypes.

Tables

Key resources table
Reagent type
(species) or resource
DesignationSource or referenceIdentifiersAdditional information
Genetic reagent (Danio rerio)bmpr1aap3/+This paperp3
Genetic reagent (Danio rerio)bmpr1absa0028ZIRCsa0028
Genetic reagent (Danio rerio)bmp7asb1aubSchmid et al., 2000sb1aub, RRID:ZFIN_ZDB-GENO-100415-21
Sequence-based reagentAlk 8 (Acvr1l) Morpholino 4Gene Tools LLCMO4-acvr1l (previously MO2-acvr1l)TGCCTTTCAGTATTCGCACAGCCAG
Sequence-based reagentAlk8 (Acvr1l) Morpholino 2Gene Tools LLCMO2-acvr1l (previously MO3-acvr1l)GATTCATGTTTGTGTTCAATTTCCG
Sequence-based reagentAlk6a (Bmpr1ba) Morpholino 1Gene Tools LLCMO1-bmpr1baAGAACTCCAGTGAGCCAGAGAATCC
Sequence-based reagentAlk6b (Bmpr1bb) Morpholino 1Gene Tools LLCMO1-bmpr1bbACTGCTCCACAGCTACTCCACACTG
Recombinant DNA reagentHuman ActivinA (plasmid)OrigeneCat #RC203226
INHBA, inhibinβa, ActivinA
Cloned into pCS2 backbone
Recombinant DNA reagentZebrafish bmp7a (plasmid)Schmid et al., 2000bmp7aCloned into pCS2 backbone
Recombinant DNA reagentZebrafish chordin (plasmid)Miller-Bertoglio et al., 1997chdCloned into pCS2 backbone
Recombinant DNA reagentHuman ACVR1 (plasmid)The Shore Lab. This Paper.Shen et al., 2009ACVR1Cloned into pCS2 backbone
Recombinant DNA reagentHuman ACVR1-R206H (plasmid)The Shore Lab. Shen et al., 2009ACVR1-R206HCloned into pCS2 backbone
Recombinant DNA reagentHuman ACVR1-G328R (plasmid)The Shore Lab. This Paper.(Shore et al., 2006).ACVR1-G328RCloned into pCS2 backbone
Recombinant DNA reagentMouse Acvr1 (plasmid)Haupt et al., 2014Cloned into pCS2 backbone
Recombinant DNA reagentMouse Acvr1-R206H (plasmid)Haupt et al., 2014p.R206HCloned into pCS2 backbone
Recombinant DNA reagentMouse Acvr1-G328R (plasmid)Haupt et al., 2014p.G328RCloned into pCS2 backbone
Recombinant DNA reagentMouse ΔAcvr1 (plasmid)Haupt et al., 2014ΔLBD-Acvr1Cloned into pCS2 backbone
Recombinant DNA reagentMouse ΔAcvr1-R206H (plasmid)Haupt et al., 2014ΔLBD-Acvr1Cloned into pCS2 backbone
Recombinant DNA reagentMouse ΔAcvr1-G328R (plasmid)Haupt et al., 2014ΔLBD-Acvr1Cloned into pCS2 backbone
AntibodyAnti-pSmad1/5/8 (rabbit monoclonal)Cell SignalingCat #13820
RRID:AB_2493181
IF (1:200)
AntibodyAnti-pSmad2/3 (rabbit monoclonal)Cell SignalingCat #8828, RRID:AB_2631089IF (1:800)
AntibodyAnti-Beta catenin (mouse monoclonal)SigmaCat #C7207, RRID:AB_476865IF (1:1000)
AntibodyAnti-HA (rabbit polyclonal)InvitrogenCat #71–5500, RRID:AB_87935IF (1:500)
AntibodyAnti-Flag (rabbit polyclonal)SigmaCat #F7425, RRID:AB_439687IF (1:500)
AntibodyAnti-rabbit Alexa 647 (goat polyclonal)InvitrogenCat #A-21245, RRID:AB_2535813IF (1:500)
AntibodyAnti-mouse Alexa 594 (goat polyclonal)Molecular ProbesCat #A21123, RRID:AB_141592IF (1:500)
OtherSytox greenFisherCat #S7020IF (1:2000)
Sequence-based reagentpax2.1 zebrafishin situ probeKrauss et al., 1992
Sequence-based reagentkrox20 zebrafishin situ probeOxtoby and Jowett, 1993
Sequence-based reagentmyod zebrafishin situ probeWeinberg et al., 1996
Commercial assay, KitmMESSAGE mMACHINE
SP6 Transcription Kit
ThermoFisherCat #AM1340
Software, algorithmFiji (ImageJ)Fijihttps://fiji.sc/#download
Software, algorithmImarisOxford InstrumentsImaris 9.6https://imaris.oxinst.com/

Additional files

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Robyn S Allen
  2. Benjamin Tajer
  3. Eileen M Shore
  4. Mary C Mullins
(2020)
Fibrodysplasia ossificans progressiva mutant ACVR1 signals by multiple modalities in the developing zebrafish
eLife 9:e53761.
https://doi.org/10.7554/eLife.53761